https://doi.org/10.4081/ejtm.2022.10781
Pharmacological treatment of presbyopia: A systematic review
Submitted: 5 August 2022
Accepted: 9 August 2022
Published: 19 September 2022
Accepted: 9 August 2022
Abstract Views: 1472
PDF: 1060
HTML: 62
HTML: 62
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The aim of this study was to identify the efficacy of drug agents for pharmacological Treatment of Presbyopia. Published research papers were reviewed using the relevant terms in PubMed, Science direct, Google scholar, Medline, Google patent, Ovid, Cochrane Database of Systematic Reviews, Scopus. In the initial search, 2270 records were obtained. By removing duplicate articles and all articles that did not meet the inclusion criteria or were inappropriate due to indirect relevance to the subject, 44 studies were selected. It should be noted that all studies had inclusion criteria. There are a number of topical pharmacological agents available for treating presbyopia such as FOV Tears and PresbiDrop. They consist of parasympathetic agent and non-steroidal anti-inflammatory drugs (NSAIDs), to contract the ciliary and pupil muscle and restore the accommodation. Another example of topical pharmacological agent is EV06. It is a lens-softening eye drop which can affect the rigid lens in presbyopia. Currently there is no pharmacological agent available to treat presbyopia. Although there are limited number of peer-reviewed articles available, the outcome for future agents under investigation are promising.
Frick KD, Joy SM, Wilson DA, Naidoo KS, Holden BA. The Global Burden of Potential Productivity Loss from Uncorrected Presbyopia. Ophthalmology. 2015 Aug;122(8):1706-10.
DOI: https://doi.org/10.1016/j.ophtha.2015.04.014
Nakazawa Y, Aoki M, Doki Y, Morishita N, Endo S, Nagai N, Funakoshi-Tago M, Tamura H. Oral consumption of α-glucosyl-hesperidin could prevent lens hardening, which causes presbyopia. Biochem Biophys Rep. 2020 Dec 26;25:100885.
DOI: https://doi.org/10.1016/j.bbrep.2020.100885
Koopmans SA, Terwee T, Barkhof J, Haitjema HJ, Kooijman AC. Polymer refilling of presbyopic human lenses in vitro restores the ability to undergo accommodative changes. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):250-7.
DOI: https://doi.org/10.1167/iovs.02-0256
Ayaki M, Tsuneyoshi Y, Yuki K, Tsubota K, Negishi K. Latanoprost could exacerbate the progression of presbyopia. PLoS One. 2019 Jan 31;14(1):e0211631.
DOI: https://doi.org/10.1371/journal.pone.0211631
U.S. Census Bureau. International data base of world population by age and sex (year 2015 selected). [Internet].2016. [cited 28 Apr 2021] [about one page] https://www.census.gov/population/international/data/idb/worldpop.php
Renna A, Vejarano LF, De la Cruz E, Alió JL. Pharmacological Treatment of Presbyopia by Novel Binocularly Instilled Eye Drops: A Pilot Study. Ophthalmol Ther. 2016 Jun;5(1):63-73. doi: 10.1007/s40123-016-0050-x. Epub 2016 May 11.
DOI: https://doi.org/10.1007/s40123-016-0050-x
Encyclopedia M. Presbyopia: MedlinePlus Medical Encyclopedia [Internet]. Medlineplus.gov. 2021 [cited 2021 Mar 30]. https://medlineplus.gov/ency/article/001026.htm
Grzybowski A. Pharmacological treatment of presbyopia. Acta Ophthalmol [Internet]. 2019 [cited 2021 Apr 26];97(S263). https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2019.809
DOI: https://doi.org/10.1111/j.1755-3768.2019.8091
Moorfields Eye Hospital to close its specials manufacturing facility. The Pharmaceutical Journal [Internet]. 2015; [cited 2021 Apr 26]; [about 1 page]. Presbyopia - Conditions - Moorfields Eye Hospital.
Grzybowski A, Markeviciute A, Zemaitiene R. A Review of Pharmacological Presbyopia Treatment. Asia Pac J Ophthalmol (Phila) [Internet]. 2020 [cited 2021 Apr 26];9(3):226-233.
DOI: https://doi.org/10.1097/APO.0000000000000297
Benozzi G, Perez C, Leiro J, Facal S, Orman B. Presbyopia Treatment With Eye Drops: An Eight Year Retrospective Study .Transl Vis Sci Technol [Internet]. June 2020 [cited 2021 Apr 26]; Vol.9, 25.
Balgos MJTD, Vargas V, Alio´ JL. Correction of presbyopia: an integrated update for the practical surgeon.Taiwan J Ophthalmol [Internet]. Jul-Sep 2018 [cited 2021 Apr 28];8(3):121-140.
DOI: https://doi.org/10.4103/tjo.tjo_53_18
Alio JL, Plaza-Puche AB, Fernandez-Buenaga R, Pikkel J, Maldonado M. Multifocal intraocular lenses: an overview. Surv Ophthalmol [Internet].2017[cited 2021 Apr 28]; 62:611–634.
DOI: https://doi.org/10.1016/j.survophthal.2017.03.005
Charman WN. Developments in the correction of presbyopia II: surgical approaches. Ophthalmic Physiol Opt. [Internet] 2014 Jul [cited 28 Apr. 21];34(4):397-426. doi: 10.1111/ opo.12129.
DOI: https://doi.org/10.1111/opo.12129
Renna A, Alió J, Vejarano L. Pharmacological treatments of presbyopia: a review of modern perspectives. Eye Vis [Internet]. 2017 [cited 2021 Apr 26];4(1).
DOI: https://doi.org/10.1186/s40662-017-0068-8
Vargas V, Vejarano F, Alió J. Near Vision Improvement with the Use of a New Topical Compound for Presbyopia Correction: A Prospective, Consecutive Interventional Non-Comparative Clinical Study. Ophthalmol Ther [Internet]. 2018 [cited 2021 Apr 26];8(1):31-39.
DOI: https://doi.org/10.1007/s40123-018-0154-6
Hernandez VR ,Diaz HC. Eurocanarias Oftalmologica. Ophthalmic composition for the correction of presbyopia. European Patent Office [Internet]. EP 2 886 113 A1.2015. March 30. [cited 2021 Apr 26] EP2886113A1 - Ophthalmic composition for the correction of presbyopia - Google Patents.
Facal S, Leiro J, Gualtieri A, Perez C, Benozzi G, Orman B. Ocular Surface Evaluation in Patients Treated with Pharmacological Treatment for Presbyopia. Int J Ophthalmic Pathol [Internet]. 2018 [cited 2021 March 26];07(02).
DOI: https://doi.org/10.4172/2324-8599.1000218
Benozzi JL. Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia. United State [Internet]. patent US 8,524,758 B2.2013. March 30. [cited 2021 Apr 26]. US8524758B2 - Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia - Google Patents
Restrepo LFV, Ophthalmic formulation and method for ameliorating presbyopia. United State [Internet]. Patent US 2014/0024642 A1. 2014.March 30. [cited 2021 Apr 26]. US20140024642A1 - Ophthalmic formulation and method for ameliorating presbyopia - Google Patents
Claes G. Feinblaum, Patel S, Šalamun F. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration. WIPO(PCT) [Internet]. patent WO 2015/122853 Al.2015.March 30. [cited 2021 Apr 26]. WO2015122853A1 - Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration - Google Patents
Ricciotti E, FitzGerald GA. Prostaglandins, and inflammation. Arterioscler Thromb Vasc Biol. [Internet] 2011;31(5):986-1000. [cited :2021 Apr 26]
DOI: https://doi.org/10.1161/ATVBAHA.110.207449
Abdelkader A. Improved Presbyopic Vision With Miotics. Eye Contact Lens 2015; 41:323–327.
DOI: https://doi.org/10.1097/ICL.0000000000000137
Kaufman S. Addressing presbyopia pharmacologically. Ophthalmology Times. 2012. Available at https://www.ophthalmologytimes.com/article/addressing-presbyopia-pharmacologically. Last accessed February 8, 2022.
Benozzi, J, Benozzi, G, Orman B. Presbyopia: a New Potential Pharmacological Treatment. Med Hypothesis Discov Innov Ophthalmol [Internet]. 2012 [cited 2021 Apr 26] Spring; 1(1): 3–5. Presbyopia: a New Potential Pharmacological Treatment (nih.gov).
Addressing presbyopia pharmacologically [Internet] 2021[cited 2021 Mar 30]. Ophthalmology Times. https://www.ophthal mologytimes.com/ view/addressing-presbyopia-pharmacologically.
Abdelkader A, Kaufman HE. Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia. Eye Vis (Lond). 2016 Dec 5;3:31.
DOI: https://doi.org/10.1186/s40662-016-0065-3
Korenfeld MS, Robertson SM, Stein JM, Evans DG, Rauchman SH, Sall KN, Venkataraman S, Chen BL, Wuttke M, Burns W. Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial. Eye (Lond). 2021 Dec;35(12):3292-3301. Epub 2021 Jan 29.
DOI: https://doi.org/10.1038/s41433-020-01391-z
Tsuneyoshi Y, Higuchi A, Negishi K, Tsubota K. Author Correction: Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy. Sci Rep. 2020 Apr 16;10(1):6757. Erratum for: Sci Rep. 2017 Jul 28;7(1):6819.
DOI: https://doi.org/10.1038/s41598-020-62436-7
Gwon A ,EWoldeMussie. Allergan Inc Vision Pharmaceuticals LP. Cholinergic agents in the treatment of presbyopia. United State [Internet]. patent US 6,291,466 B1.2001 March 30. [cited 2021 Apr 26]. https://patents.google.com/patent/US6291466B1/en
Karanfil F, Turgut B. Update on Presbyopia-correcting Drops. European Ophthalmic Review [Internet]. 2017 [cited 2021 Arp 26];11(02):99.
DOI: https://doi.org/10.17925/EOR.2017.11.02.99
Abad JC. Allergan Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism. United State [Internet]. patent US 2020/0069651 A1.2020. March 30. [cited 2021 Apr 26]. US20200069651A1 - Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism - Google Patents.
How to Cite
Haghpanah, N., & Alany, R. (2022). Pharmacological treatment of presbyopia: A systematic review. European Journal of Translational Myology, 32(3). https://doi.org/10.4081/ejtm.2022.10781
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.